ImaRx’ Combo Treatment For Stroke To Wrap Up Phase I/II Trial By Mid-2008
This article was originally published in The Gray Sheet
Executive Summary
ImaRx is on track to complete enrollment in a Phase I/II dose escalation study by mid-2008 for its combo product SonoLysis, which uses ultrasound and microbubbles to treat acute ischemic stroke
You may also be interested in...
Combo Product Excitement: Large Players On Look-Out For Early-Stage Deals
Heightened corporate interest in innovative drug-delivery technologies offers greater opportunities for small device firms to attract larger company investment, venture capitalists say
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.